Attruby
(acoramidis)ApprovedSmall molecule
Acoramidis is used to treat a heart condition where an abnormal protein builds up in the heart muscle, making it thick and stiff so the heart cannot pump blood effectively. The medication works by stabilizing the protein and preventing it from damaging the heart.[2] Attruby is currently approved and in use across 3 indications[4].[1]
Attruby is one of 79 small molecule programs targeting Cardiomyopathy. It is currently in Approved.
3
Indications
10
Total Trials
6
Active Trials
78
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
13
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
91 competitors in Cardiomyopathy
#DrugCompanyPhaseTrials
1Attruby
NNavire Pharma Inc., a BridgeBio company
Approved
Dobutrex
Eli LillyPhase 3
Plaquenil
Alnylam PharmaceuticalsPhase 3
Vyndaqel
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Wainua (autoinjector)
AstraZenecaPhase 3
Immunoglobulins
CSL BehringPhase 3
Cialis
Eli LillyPhase 2
Aldactone
PfizerPhase 2
Cellcept
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Single Dose2 trials
Transthyretin Amyloid Cardiomyopathy2 trials
Efficacy and Safety1 trial
Biomarkers1 trial
Regulatory
FDA Approval Timeline[5]
Nov 22, 2024
ATTRUBY
NDA NDA216540
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Attruby drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for acoramidis. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]